A safety and efficacy clinical study of a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCID（severe combined immune deficiency ）.The ten children will be followed for 3-5 years and be evaluated by clinical characteristics, vector marking (vector copy number per cell) in blood and bone marrow cells, immune reconstitution vector insertion-site patterns and so on.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
1-year survival rate 1-year survival rate
Timeframe: one year after gene therapy of last recruited patient
3-year survival rate
Timeframe: three years after gene therapy of last recruited patient
5-year survival rate
Timeframe: five years after gene therapy of last recruited patient